Biosimilar competition may take a bigger bite out of branded sales than we think. The top 10 biologics facing biosimilar competition will see sales fall to $49 billion by 2020, consensus estimates say. That's down from $62 billion last year. But according to Morningstar analysts, that 2020 sales number is too high.
Industry watchers expect biosimilars for AbbVie's Humira to be the most successful copycat biologics launched in the U.S. and Europe, and that's something Merck and Samsung are trying to get in on.
With biosimilars makers eager to grab a piece of Humira's $12.5 billion-plus revenue, copies of AbbVie's blockbuster are on their way. What analysts disagree on, though, is when they'll arrive and how long it'll take them to make their presence known--and a pair of UBS analysts, for one, thinks the Illinois pharma has some marketing maneuvers up its sleeve to minimize their impact.
Drug companies in India's leading industrial state of Gujarat, the base of Prime Minister Narendra Modi, are stepping up efforts to crack the domestic market for biosimilars as well as abroad, Business Standard reports.
The cost-effectiveness watchdogs at the National Institute for Health and Care Excellence have put their money behind biosimilars. Remicade biosimilars, to be exact, in new guidance for treating rheumatoid arthritis.
A move by Australia to be the first country to allow pharmacies in some cases to substitute biosimilars for originator drugs has drawn a rebuke by the U.S.-based Alliance for Safe Biologic Medicines, which includes members such as Amgen and the Biotechnology Industry Organization.
Novartis' eye drug Lucentis has long had a target on its back from biosimilar makers who would love to get some piece of the $4 billion in annual sales it racks up. Now an Indian drugmaker says it has hit that mark.
Here's something AbbVie doesn't want to hear: Industry watchers expect biosimilars for its top moneymaker Humira to be the most successful copycat biologics launched in the U.S. and Europe.
Amgen is none too eager for Novartis to roll out its newly FDA-approved biosimilar version of its blockbuster Neupogen, and for now, it's getting its way: A U.S. appeals court has blocked sales of the copycat while the companies resolve a patent dispute.
Nearly a dozen makers of biosimilars, including Hospira, Pfizer, Samsung and Sandoz, have banded together into the Biosimilars Forum, a nonprofit group that will lobby for how biosimilars are used in the U.S.